The new regulatory scheme poses problems – but also opportunities, in the shape of possible alignment with the US.
Software-enabled medical devices pose unique challenges to regulators, and the US agency is getting serious about meeting them.
The new price for its Covid-19 vaccine is lower than earlier deals – but arguably not by much.
By signalling that its Covid-19 vaccine could cost just a few dollars Astra could seriously embarrass its competition.
There was a time when President Trump could mention drug pricing controls and move markets. Now, not so much.
EQRX has closed two early-stage licensing deals to bring in small molecules that it hopes will shake up oncology pricing.
By pricing remdesivir at $2,340 for a five-day course Gilead has kept investors on side, but others will be disappointed.
Gilead has been rewarded handsomely, via share price gains, for its Covid-19 remdesivir work, but the potential costs should not be forgotten.